1. A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors
- Author
-
Guilherme Targino Valente, Heloisa de Carvalho Sampaio, Leonardo Nazario de Moraes, Ivan Rodrigo Wolf, David Perahia, Giovanni Faria Silva, Angelo J. Magro, Lauana Fogaça, Rafael Plana Simões, Rejane Maria Tommasini Grotto, Universidade Estadual Paulista (Unesp), Max Planck Institut for Heart and Lung Research, and Laboratory of Biology and Applied Pharmacology
- Subjects
Models, Molecular ,Cancer Research ,Mutation rate ,Proline ,medicine.medical_treatment ,Hepacivirus ,Biology ,Viral Nonstructural Proteins ,medicine.disease_cause ,Direct-acting antiviral ,Antiviral Agents ,Virus ,03 medical and health sciences ,chemistry.chemical_compound ,Virology ,Boceprevir ,Drug Resistance, Viral ,medicine ,Resistance associated substitutions ,Humans ,Protease Inhibitors ,030304 developmental biology ,chemistry.chemical_classification ,Genetics ,0303 health sciences ,Mutation ,NS3 ,Protease ,030306 microbiology ,Hepatitis C, Chronic ,Infectious Diseases ,Enzyme ,chemistry ,Treatment failure ,HCV ,Viral load - Abstract
Made available in DSpace on 2020-12-12T00:56:54Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-12-01 NS3 is an important therapeutic target for direct-acting antiviral (DAA) drugs. However, many patients treated with DAAs have unsustained virologic response (UVR) due to the high mutation rate of HCV. The aim of this work was to shed some light on the puzzling molecular mechanisms of the virus's of patients who showed high viral loads even under treatment with DAA. Bioinformatics tools, molecular modelling analyses were employed to identify mutations associated with HCV resistance to boceprevir and possible structural features related to this phenomenon. We identified two mutations of NS3 that may be associated with HCV resistance: D168N and L153I. The substitution D168N was previously reported in the literature as related with drug failure. Additionally, we identified that its molecular resistance mechanism can be explained by the destabilization of receptor-ligand hydrogen bonds. For the L153I mutation, the resistance mechanism is different from previous models reported in the literature. The L153I substitution decreases the S139 deprotonation susceptibility, and consequently, this mutation impairs the covalent binding between the residue S139 from NS3 and the electrophilic trap on boceprevir, which can induce drug failure. These results were supported by the time course analysis of the mutations of the NS3 protease, which showed that boceprevir was designed for enzymes with an L residue at position 153; however, the sequences with I153 are predominant nowadays. The results presented here could be used to infer about resistance in others DAA, mainly protease inhibitors. Sao Paulo State University (UNESP) School of Agriculture Department of Bioprocess and Biotechnology, Avenue Universitária Sao Paulo State University (UNESP) Medical School Blood Center, Avenue Prof. Mário Rubens Guimarães Montenegro, s/n Max Planck Institut for Heart and Lung Research, Ludwigstraße 43 Sao Paulo State University (UNESP) Institute of Biosciences, Street Prof. Dr. Antônio Celso Wagner Zanin, 250 École Normale Supérieure Paris-Saclay Laboratory of Biology and Applied Pharmacology Sao Paulo State University (UNESP) School of Agriculture Department of Bioprocess and Biotechnology, Avenue Universitária Sao Paulo State University (UNESP) Medical School Blood Center, Avenue Prof. Mário Rubens Guimarães Montenegro, s/n Sao Paulo State University (UNESP) Institute of Biosciences, Street Prof. Dr. Antônio Celso Wagner Zanin, 250
- Published
- 2019